Postgraduate medicine···
Expert guidelines for medication treatment of bipolar disorder (2000)
Updated
Abstract
Consensus was reached on 1,276 treatment options for bipolar disorder across 48 clinical situations.
- A mood stabilizer is recommended in all phases of treatment.
- Divalproex and lithium are identified as cornerstone choices for both acute and preventive treatment of mania.
- If monotherapy fails, combining mood stabilizers is the next recommended intervention.
- For milder depression, lithium may be used as monotherapy, with divalproex and lamotrigine as other first-line options.
- A standard antidepressant should be combined with lithium or divalproex for more severe depression.
- Atypical antipsychotics, especially olanzapine and risperidone, are preferred for managing mania or depression with psychosis.
Simplified
OBJECTIVES: New treatments for bipolar disorder have been reported since we first published survey-based expert consensus guidelines in 1996. The evidence for these treatments varies widely; data are especially limited regarding comparisons between treatments and how to sequence them. We therefore undertook a new survey of expert opinion in order to bridge gaps between the research evidence and key clinical decisions.
METHOD: Based on a literature review, a written survey was prepared which asked about 1,276 options for psychopharmacologic interventions in 48 specific clinical situations. Most options were scored using a modified version of the RAND Corporation 9-point scale for rating appropriateness of medical decisions. We contacted 65 national experts, 58 of whom (89%) completed the survey. Consensus on each option was defined as a non-random distribution of scores by chi-square test. We assigned a categorical rank (first-line/preferred choice, second-line/alternate choice, third-line/usually inappropriate) to each option based on the confidence interval of its mean rating. Guideline tables indicating preferred treatment strategies were then developed for key clinical situations.
RESULTS: The expert panel reached consensus on many key strategies, including acute and preventive treatment for mania (euphoric, mixed, and dysphoric subtypes), depression, and rapid cycling, and approaches to managing the complications of treatment resistance and comorbidity. Use of a mood stabilizer is recommended in all phases of treatment. Divalproex (especially for mixed or dysphoric subtypes) and lithium are the cornerstone choices among this class for both acute and preventive treatment of mania. Regardless of which is selected first, if monotherapy fails, the next recommended intervention is to use these agents in combination. The combination can then serve as the foundation on which other medications are added, if needed. Carbamazepine is the leading alternative mood stabilizer for mania. Expert opinion regards other new anticonvulsants as second-line options (e.g., if the previously mentioned mood stabilizers fail or are contraindicated). For milder depression, a mood stabilizer, especially lithium, may be used as monotherapy. Divalproex and lamotrigine are other first-line choices. For more severe depression, a standard antidepressant should be combined with lithium or divalproex. Bupropion, selective serotonin reuptake inhibitors (SSRIs), and venlafaxine are preferred antidepressants, and should be tapered 2 to 6 months after remission. Divalproex monotherapy is recommended for initial treatment of either depression or mania with rapid cycling. Antipsychotics are recommended for use with the above regimens for mania or depression with psychosis, and as potential adjuncts in non-psychotic episodes. Atypical antipsychotics, especially olanzapine and risperidone, were generally preferred over conventional antipsychotics. Recommendations are also given concerning the use of electroconvulsive therapy (ECT), clozapine, thyroid hormone, stimulants, and various novel agents for patients with treatment-refractory illness.
CONCLUSIONS: The experts reached high levels of consensus on key steps in treating bipolar disorder despite obvious gaps in high-quality data. To evaluate many of the treatment options in this survey, the experts had to extrapolate beyond controlled data; however, their recommendations are generally conservative. Experts reserve strongest support for initial strategies and individual medications for which there are high-quality research data, or for which there are longstanding patterns of clinical usage. Within the limits of expert opinion and with the understanding that new research data may take precedence, these guidelines provide clear pathways for addressing common clinical questions in a manner that can be used to inform clinicians and educate patients regarding the relative merits of a variety of interventions.
Related papers
Mar '04
Use of Antipsychotic Medicines in Older Adults
cited by 108 papers
consensus statement
Dec '03
Guidelines for Improving Medication Treatment of Psychotic Disorders: Introduction, Methods, and Summary
cited by 112 papers
practice guideline
Jul '05
Medication guidelines for treating bipolar disorder in 2000
cited by 16 papers
journal article
Jan '07
Guidelines for Treating Dementia and Its Behavioral Symptoms: Introduction, Methods, and Overview
top 30% journal
cited by 40 papers
research support, non-u.s. gov't
Aug '01
Expert Guidelines for Treating Urgent Behavioral Crises
top 30% journal
cited by 42 papers
guideline
Dec '07
Expert advice on treating epilepsy in children in Europe, 2007
top 30% journal
cited by 205 papers
research support, non-u.s. gov't
Feb '07
Treatments for bipolar disorder in older adults
cited by 89 papers
research support, u.s. gov't, p.h.s.
Dec '05
Expert Guidelines for Treating Urgent Behavioral Crises (2005)
cited by 172 papers
practice guideline
Jan '07
Medication Treatment Guidelines for Depression in Older Adults
top 30% journal
cited by 47 papers
practice guideline